Sun, Dec 28, 2014, 5:38 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

EDAP TMS SA Message Board

  • my_honest_always my_honest_always Feb 19, 2013 9:43 PM Flag

    A sad day today because I have sold my 40,000 shares.

    I thought I made a very good DD on EDAP. I was and I am still confident in this technology because she a good one. But after reading again and again all the posts here I have discovered other facts I didn't know. I have discovered that as soon as EDAP will be approved a US competitor will be also approved and is already prepared to submerge the market with a better HIFU (more expensive but more precise). I was thinking that EDAP would have had a possibility to have several years to produce, make profit and so on. But I have realised that I was wrong. I have made a lost by selling but I think my money will be better in another company.
    It's not bashing at all: it's just my personal feeling and I have learnt the hard way to listen to my feelings and moreover to the tough facts.

    I wish you all a tremendous success and if you are making huge profit I will be glad for you all.

    We cannot buy the faith in a stock. We have to follow our gut feeling.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • puhhhllleeeeeeeeeeeezzzzzzzzzzzzzzzzz. you need therapy and medication. scuz me while i puke.
      strong buy.

      Sentiment: Strong Buy

    • hahahaah you are not very smart!

    • I'm guessing you are much sadder today?

    • The WEEK Get crushed
      over 250K shares and holding

      Sentiment: Strong Buy

    • sold to soon

    • Honest_always, I'm writing you to apologize. That was dumb of me to write that. I should not have been so brash. In truth, I haven't done the kind of DD that you have. I wrote that message in a brief fit of impatience and insolence. I feel badly. I hope you can forgive me. You're right, I should probably get a life.

      Best of luck to you. I hope, sincerely, that your investment decisions bring you the prosperity and peace of mind that I am sure you deserve. In the future, I'll refrain from being the idiot I made myself out to be in my mean post to you.

      Sincere regards,
      G

      Sentiment: Strong Buy

    • Ok,
      get lost now....

      Sentiment: Strong Buy

    • Your so wrong and the S 500 is no match for the EDAP system Do your research

    • It's clear from your message that you are lying. Sorry, pal. Unless you can name this US competitor, your message has no credibility.

      Sentiment: Strong Buy

    • name of competitor,
      would you mind supplying the name of the us competitor to edap

      • 1 Reply to canacejohn
      • Just Google : Focus Surgery, Inc. develops and commercializes high intensity focused ultrasound products for the treatment of prostate diseases. The company offers Sonablate 500 system, an image-guided acoustic ablation device for treatment planning and monitoring, and targeted and noninvasive tissue treatment. It offers its products through distributors in the United States and internationally. The company was founded in 1996 and is based in Indianapolis, Indiana. Focus Surgery, Inc. operates as a subsidiary of USHIFU, LLC.

        Also :

        Sonablate® 500 approved to treat Prostate Cancer with High Intensity Focused Ultrasound in Mexico


        CHARLOTTE, NC, August 2, 2004 - On July 26, 2004 the Mexican Ministry of Health granted approval to U.S. HIFU, a development company based in Charlotte, NC, for the use of the Sonablate® 500 in Mexico for the treatment of prostate cancer with High Intensity Focused Ultrasound, or HIFU, technology. This is the first HIFU technology officially approved in Mexico.

        The Sonablate 500®, developed by Focus Surgery Inc. of Indianapolis, IN, is a noninvasive therapy device that uses the power of ultrasound to destroy deep seated tissue without affecting healthy surrounding tissue. Ultrasound energy is non-ionizing "clean energy" that does not affect tissue surrounding the target zone, as opposed to radiation therapies. The treatment usually can be given in one to three hours on an outpatient basis with epidural anesthesia.

        Steve Puckett, Jr., chief executive officer of U.S. HIFU said, "Mexican approval for the Sonablate® 500 marks a new chapter in the fight against prostate cancer in the region. Mexican patients now have access to the most advance prostate cancer treatment available today."

        In 2001, the Sonablate® 500 received approval in Europe and Japan. The device is also approved for use in the Dominican Republic.

        Although the Sonablate® 500 is only approved for investigational use within the United States U.S. HIFU executives are eager to offer HIFU to as many people as possible. "U.S. HIFU will not rest until this treatment option is available throughout all of the Americas," Puckett said.

        The American Cancer Society reported in 2000 that 16.6 men out of 100,000 will die of prostate cancer in Mexico. The mortality rating is only slightly higher in the United States where on average 17.9 of 100,000 men will die of prostate cancer. Early prostate cancer has few symptoms and the only risk factors are age, ethnicity and family history of the disease. Early detection with a digital rectal exam and a blood test to detect levels of prostate-specific antigen (PSA) are essential for being treated successfully.

        U.S. HIFU is the exclusive distributor of the Sonablate® 500 in North, Central and South America including island nations of the Caribbean. The company also holds a minority ownership position in Focus Surgery. U.S. HIFU's investment in Focus Surgery will help fund Phase II-III U.S. clinical trials of the Sonablate® 500 which are scheduled to begin later this year.

 
EDAP
2.01+0.0400(+2.03%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.